Oric Pharma Rg

Oric Pharma Rg, a clinical‑stage biopharma, develops cancer resistance therapies. Lead candidates ORIC‑114 (Phase 1b EGFR/ERBB2 exon 20 inhibitor) and ORIC‑944 (Phase 1b prostate CRPC allosteric CR2 inhibitor) partner with Pfizer, Bayer, J&J.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 106
HQ: South San Francisco

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
ORIC	Oric Pharma Rg Cap: 0.9B	EQUITY	NMS	USD	US68622P1093	Active	📈